When the medication isn't working
Tesamorelin: Egrifta Uses, Belly Fat Data, Side Effects
What tesamorelin is, the FDA-approved Egrifta indication for HIV lipodystrophy, what the belly fat trials found, label side effects, compounded and off-label use, and how it compares with ipamorelin.
Last reviewed
The Vital angle
Vital's peptide directory has a tesamorelin profile with its FDA status, evidence level, mechanism, half-life, known side effects, and a link to the prescribing information. When you log a dose, you can save the source type, lot number, injection site, and any symptoms with a severity, so the record is ready for your prescriber's IGF-1 and glucose checks.
What tesamorelin is
Tesamorelin is a synthetic version of growth hormone-releasing hormone (GHRH), the signal that the hypothalamus sends to the pituitary gland. It is made of the 44 amino acids of human GHRH with a small chemical chain added. That chain makes it more stable in the body. Tesamorelin causes the pituitary to release more of the body's own growth hormone, which raises IGF-1, a growth factor made mostly in the liver.
Tesamorelin is an FDA-approved drug, which makes it different from most peptides in wellness clinics. Theratechnologies sells it in the United States as Egrifta. The current form on the FDA label is Egrifta WR. The approval covers one narrow use, and much of the current interest is outside that use.
This guide explains the approved indication, what the trials showed, the label warnings, and the questions to ask before off-label or compounded use. It is not medical advice and does not give doses. Ask your prescriber about any treatment decision.
The FDA-approved indication: HIV lipodystrophy
The FDA first approved tesamorelin in November 2010. The Egrifta WR label says it is indicated for the reduction of excess abdominal fat in HIV-infected adult patients with lipodystrophy. Lipodystrophy is a change in body fat distribution. Some people with HIV gain deep belly fat around the organs, called visceral adipose tissue, while they lose fat in the face, arms, or legs.
The label also lists limits of use:
- It is not indicated for weight loss management, because it has a weight-neutral effect.
- Long-term cardiovascular safety is not established.
- There are no data that it improves adherence to HIV medicines.
Any use for general belly fat, body composition, or anti-aging in people without HIV lipodystrophy is off-label. A prescriber can legally prescribe a drug off-label, but no trial has shown the same benefit and safety balance in those groups.
Tesamorelin and belly fat: what the trials found
The main evidence for tesamorelin belly fat claims comes from two phase 3 trials in adults with HIV and excess abdominal fat. In the first trial, published in the New England Journal of Medicine in 2007, 412 people received daily tesamorelin or placebo for 26 weeks. CT scans measured visceral fat at the start and at the end.
- Visceral fat fell 15.2% on tesamorelin and rose 5.0% on placebo.
- Triglycerides fell on tesamorelin.
- On the label, trunk fat fell and lean body mass rose slightly on tesamorelin.
- Total body weight did not change much, which matches the label's "weight neutral" statement.
A second phase 3 trial found a smaller but similar drop in visceral fat. These results apply to people with HIV lipodystrophy under medical supervision, with brand-name product. They do not show that tesamorelin reduces belly fat in people without HIV, and they do not measure long-term health outcomes such as heart attacks.
Tesamorelin side effects and warnings
The Egrifta WR label lists the most common tesamorelin side effects, each in more than 5% of patients:
- Joint pain (arthralgia)
- Injection site redness and itching
- Pain in the arms or legs
- Swelling in the legs or ankles (peripheral edema)
- Muscle pain
Injection site reactions occurred in 25% of people on tesamorelin and 14% on placebo during the first 26 weeks. The label tells patients to rotate sites within the abdomen. Our guide to peptide injection site reactions explains what is usually normal and what needs care.
The label also gives these warnings:
- IGF-1 rise. Tesamorelin increases IGF-1, and the effects of long-term high IGF-1 are unknown. After 26 weeks, 47% of patients had IGF-1 levels more than 2 standard deviations above normal. The label tells prescribers to monitor IGF-1.
- Glucose changes. Tesamorelin can cause glucose intolerance or diabetes. The label says to check glucose before and during treatment.
- Fluid retention. Swelling, joint pain, and carpal tunnel syndrome can occur.
- Hypersensitivity. Reactions such as itching, flushing, hives, and rash occurred in 4% of patients in trials.
- Cancer. It must not be used with active cancer, and any past cancer must be inactive before treatment.
The label lists these contraindications: pregnancy, active cancer, known allergy to tesamorelin, and a damaged hypothalamic-pituitary system, such as after pituitary surgery, head radiation, or head injury.
Compounded and off-label tesamorelin
Many clinics offer compounded tesamorelin for body composition. Compounded tesamorelin has a specific regulatory problem, separate from the general risks of compounding.
On March 23, 2020, the FDA moved Egrifta to the list of products deemed to be biologics. FDA states that federal law gives no legal pathway to market a biologic prepared outside an approved biologics license. Products regulated as biologics are not eligible for the 503A and 503B compounding exemptions. So, the legal status of a vial labeled "compounded tesamorelin" is unclear at best. Products sold online as "research use only" are not approved drugs and are not made under pharmaceutical controls.
Before you use any product that is not Egrifta from a licensed pharmacy, ask these questions:
- Is the product the FDA-approved brand, or something else?
- Which pharmacy made it, and is that pharmacy licensed in your state?
- Does the label show the strength, the lot number, and the expiration date?
- Who will check your IGF-1 and glucose, and how often?
Our guides to compounded vs brand semaglutide and peptide catalog source checks explain the same quality questions for other products. If a prescriber gives you a vial to mix, read how to reconstitute peptides with BAC water and confirm every draw with your pharmacist.
Tesamorelin vs ipamorelin
People often compare tesamorelin vs ipamorelin because both raise growth hormone. They work on different receptors and have very different regulatory status.
| Tesamorelin | Ipamorelin | |
|---|---|---|
| Type | GHRH analog | Growth hormone secretagogue (ghrelin receptor) |
| FDA status | Approved as Egrifta for HIV lipodystrophy | Not an FDA-approved drug |
| Human evidence | Two phase 3 trials, CT-measured visceral fat | Small, early studies |
| FDA compounding position | Regulated as a biologic since 2020 | Listed in Category 2 for outsourcing facilities |
The FDA bulk substances page lists ipamorelin acetate with concerns about possible immunogenicity, unnatural amino acids, and a published study that reported serious adverse events, including death, when ipamorelin was given intravenously. Neither drug has trial evidence for general fat loss or anti-aging. Our guide on peptide cycling protocols covers ipamorelin and related peptides in more detail. If you take tesamorelin with a GLP-1 medicine, read stacking peptides with a GLP-1, because both can affect glucose.
When to get medical care
Get emergency care for swelling of the face, lips, tongue, or throat, trouble breathing, or a rash that spreads over the body. Call your prescriber soon for any of these:
- New thirst, frequent urination, or blurred vision, which can be signs of high blood sugar
- Swelling in the hands or feet, or numbness and tingling in the hand
- Joint pain that does not go away
- A hot, spreading, or painful injection site
- A new lump or any sign that a past cancer has come back
Tell every clinician that you take tesamorelin, and say whether it is the brand product or a compounded or research product. Keep the lot number, the pharmacy name, and your lab results in one record.
Egrifta® (tesamorelin) is a trademark of Theratechnologies. Vital is independent and not affiliated with these companies.
Things to watch
Practical flags drawn from prescribing information and clinical guidance. Vital surfaces these in the dose log to help you spot them early.
Compounded or "research" tesamorelin
Egrifta has been regulated as a biologic since March 23, 2020. FDA states that biologics are not eligible for the 503A and 503B compounding exemptions, and research-labeled vials are not approved drugs.
Use for general weight loss
The Egrifta WR label says tesamorelin is not indicated for weight loss management because it has a weight-neutral effect.
Diabetes or prediabetes
The label warns that tesamorelin can cause glucose intolerance or diabetes, and tells prescribers to check glucose before and during treatment.
Active or past cancer
Tesamorelin raises IGF-1, a growth factor. The label contraindicates it with active cancer and requires any past cancer to be inactive and treated first.
Pregnancy
The label contraindicates tesamorelin in pregnancy, because changing visceral fat gives no benefit in pregnancy and could harm the fetus.
Pituitary or hypothalamic damage
The label contraindicates it after pituitary surgery or tumor, hypopituitarism, head radiation, or head trauma.
Frequently asked questions
The FDA approved tesamorelin, sold as Egrifta, for the reduction of excess abdominal fat in adults with HIV and lipodystrophy. The label says it is not indicated for weight loss management.
In a 26-week trial of 412 adults with HIV and excess abdominal fat, visceral fat fell 15.2% on tesamorelin and rose 5.0% on placebo. No trial has shown the same benefit in people without HIV lipodystrophy.
The most common label side effects are joint pain, injection site redness and itching, pain in the arms or legs, leg swelling, and muscle pain. The label also warns about IGF-1 rise, glucose intolerance, fluid retention, and allergic reactions.
Egrifta has been regulated as a biologic since March 2020, and FDA states that biologics are not eligible for the 503A and 503B compounding exemptions. Ask the prescriber and the pharmacy exactly what product you are getting.
Tesamorelin is a GHRH analog and an FDA-approved drug for HIV lipodystrophy. Ipamorelin acts on the ghrelin receptor, is not an FDA-approved drug, and is listed in Category 2 of FDA's compounding safety-risk page for outsourcing facilities.
The Egrifta WR label calls its effect weight neutral. In trials it lowered deep belly fat with little change in total body weight.
Sources
- EGRIFTA WR (tesamorelin) prescribing information · U.S. Food and Drug Administration
- Metabolic Effects of a Growth Hormone-Releasing Factor in Patients with HIV · NIH / PubMed (New England Journal of Medicine, 2007)
- List of Approved NDAs for Biological Products That Were Deemed to be BLAs on March 23, 2020 · U.S. Food and Drug Administration
- Compounding and the FDA: Questions and Answers · U.S. Food and Drug Administration
- Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks · U.S. Food and Drug Administration
This page summarizes publicly available information from the sources listed above and is for educational use only. It is not medical advice. Consult a qualified healthcare professional for personal dosing guidance.
Track every shot, every change
Vital logs every GLP-1 injection and peptide dose, then surfaces patterns your scale can't show. Free on iOS and Android.
More from the Library
Compounded vs Brand Semaglutide
Compounded semaglutide and brand-name Wegovy or Ozempic are not the same product. A clear-eyed look at the actual differences in regulation, formulation, cost, and risk.
Food Noise Coming Back on a GLP-1: End-of-Week Hunger and What to Track
Food noise coming back on a GLP-1 can follow the dose week, a dose step, stress, or a product change. Here is what is known, what to track for two to four weeks, and what to ask your prescriber.
Tirzepatide Medication Level Chart: Half-Life, Steady State, and Missed Doses
A tirzepatide medication level chart and a semaglutide level chart built from label half-lives, with tables for one dose, the build-up to steady state, the weekly rise and fall, and a missed dose.
GLP-1 Not Working in the First Month: What Is Normal
Little or no weight loss in the first month on a GLP-1 is common, because the starting doses are low by design. Here is what the first weeks are for, what to watch, and when to call your prescriber.